Paragen (RGEN) news

Repligen schedules third-quarter 2026 results release, conference call

REPLIGEN <RGEN.O>: BARCLAYS RAISES TARGET PRICE TO $225 FROM $175

REPLIGEN : BARCLAYS RAISES TARGET PRICE TO $225 FROM $175

Repligen CEO Olivier Loeillot disposes of USD 1,036,823 in common shares

Repligen CEO Olivier Loeillot sold 5,535 common shares on Oct. 5 at USD 178.75 to USD 190. He exercised options for 4,202 shares at USD 154.96 on the same day. Directly owned common shares ended unchanged at 45,788. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repligen Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-065238), on October 06, 2026, and is solely responsible for the information contained therein.

US Stock Market Volatility: Repligen Plunges on October 6th Due to Acquisition Settlement, Share Dilution, and High-Level Correction

BioLife Solutions holds special shareholder meeting on merger agreement vote

BioLife Solutions held a special shareholder meeting on Oct. 5, 2026 to vote on a Repligen merger deal. Stockholders adopted the merger agreement, clearing the required vote to proceed with the transaction. An advisory resolution on merger-related compensation was approved. A resolution to allow adjournment of the meeting, if needed to seek more votes, was also approved. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-415012), on October 06, 2026, and is solely responsible for the information contained therein.

Repligen completes acquisition of BioLife Solutions in cash-and-stock deal

Repligen completed its acquisition of BioLife Solutions, expanding its cell and gene therapy tools footprint. BioLife holders received USD 11.25 per share in cash, plus 0.1442 shares of Repligen stock. Repligen plans to outline the deal’s expected effect on its 2026 financial outlook on its Q3 2026 earnings call. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repligen Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060905PRIMZONEFULLFEED9840481) on October 06, 2026, and is solely responsible for the information contained therein.

BUZZ-Freshworks stock rises ahead of inclusion in S&P SmallCap 600 Index

October 6 — Software development company Freshworks Inc (FRSH.O) saw its shares rise by 4.3% to $13.79 in pre-market trading. The company will replace BioLife Solutions (BLFS.O) in the S&P SmallCap 600 Index, effective before market open on October 8, according to an announcement released after the U.S. stock market closed on Monday. BLFS is set to be acquired later this year by Repligen Corp (RGEN.O), pending regulatory and shareholder approval. According to data from London Stock Exchange Group (LSEG), as of the previous trading session's close, FRSH had a market value of $3.45 billions. As of the last close, the stock had gained 7.9% so far this year. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the translations and provides them for the convenience of readers only. Reuters assumes no responsibility for any damage or loss resulting from the use of automated translation features.)

Replimune Receives Approval to Launch Tudriqev in the US for Melanoma

【US Stock Market Fluctuation】Repligen plummeted on October 1: High-level correction, overvaluation, and dilution from M&A

Repligen CEO Olivier Loeillot disposes of common shares worth $2,460,700

Repligen CEO Olivier Loeillot disposes of common shares worth $976,680